七年中基于社区的男性样本中良性前列腺特异性抗原和 [-2]前列腺特异性抗原的纵向变化。
Longitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men.
机构信息
Department of Epidemiology, University of Medicine and Dentistry in New Jersey, Piscataway, New Jersey, USA.
出版信息
Urology. 2012 Mar;79(3):655-61. doi: 10.1016/j.urology.2011.09.056.
OBJECTIVE
To determine the longitudinal changes of benign prostate-specific antigen (BPSA) and [-2]proPSA and how these changes relate to the outcomes. These markers have been shown to be predictive of prostate cancer (CaP) and benign prostatic hyperplasia treatment; however, little is known about longitudinal changes in these markers.
METHODS
In 1990, a 25% subsample from a cohort of white men aged 40-79 years, who were randomly selected from Olmsted County, Minnesota residents, completed a detailed clinical examination. BPSA and [-2]proPSA were measured from frozen sera. The men were evaluated biennially (median follow-up 7 years; range 0-8.8). Mixed-effects regression models were used to estimate the longitudinal changes in the BPSA and [-2]proPSA levels overall and by outcomes. Spearman correlations were used to compare these changes with the baseline levels and the annualized changes in urologic measures.
RESULTS
The median and 25th and 75th percentiles annualized percent change for [-2]proPSA and BPSA was 3.7%, 2.5% and 5.2% and 7.3%, 6.8%, and 7.7%, respectively. The annualized percent change for both markers correlated with the baseline and annualized changes in PSA and prostate volume. The annualized percent change increased with increasing age decade for [-2]proPSA but not for BPSA. The rate of increase in [-2]proPSA was significantly greater for men who developed enlarged prostates (median 3.5%, 25th and 75th percentile 2.6% and 4.4%, respectively) or CaP (median 8.1%, 25th and 75th percentile 6.6% and 9.8%, respectively) compared with those who did not develop enlarged prostates (median 1.9%, 25th and 75th percentile 0.9% and 3.0%, respectively) or CaP (median 3.5%, 25th and 75th percentile 2.3% and 4.8%, respectively).
CONCLUSION
BPSA and [-2]proPSA levels increase over time. The annualized percent change in [-2]proPSA increases with age and might be a useful predictor of CaP development.
目的
确定良性前列腺特异性抗原（BPSA）和 [-2]proPSA 的纵向变化，以及这些变化与结果的关系。这些标志物已被证明对前列腺癌（CaP）和良性前列腺增生的治疗具有预测作用；然而，关于这些标志物的纵向变化知之甚少。
方法
1990 年，从明尼苏达州奥姆斯特德县随机选择的年龄在 40-79 岁的白人男性队列中抽取了 25%的亚组，完成了详细的临床检查。从冷冻血清中测量 BPSA 和 [-2]proPSA。男性每两年评估一次（中位随访 7 年；范围 0-8.8）。使用混合效应回归模型估计 BPSA 和 [-2]proPSA 水平的总体和结果的纵向变化。Spearman 相关系数用于比较这些变化与基线水平和泌尿科测量的年化变化。
结果
[-2]proPSA 和 BPSA 的中位数和 25%和 75%分位数年化百分比变化分别为 3.7%、2.5%和 5.2%和 7.3%、6.8%和 7.7%。两种标志物的年化百分比变化与 PSA 和前列腺体积的基线和年化变化相关。对于 [-2]proPSA，年龄每增加十年，年化百分比变化就会增加，但对于 BPSA 则不然。[-2]proPSA 的增长率在前列腺增大（中位数 3.5%，25%和 75%分别为 2.6%和 4.4%）或 CaP（中位数 8.1%，25%和 75%分别为 6.6%和 9.8%）的男性中明显大于未发生前列腺增大（中位数 1.9%，25%和 75%分别为 0.9%和 3.0%）或 CaP（中位数 3.5%，25%和 75%分别为 2.3%和 4.8%）的男性。
结论
BPSA 和 [-2]proPSA 水平随时间推移而增加。[-2]proPSA 的年化百分比变化随年龄增长而增加，可能是 CaP 发展的有用预测指标。
Zotero 插件